A Phase 1 interventional study of Ethinyl Estradiol + Levonorgestrel and ABBV-722 in Healthy Volunteer, sponsored by AbbVie. Completed at 1 site in United States. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-30.
Sponsored by AbbVie · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to assess the effect of repeated doses of ABBV-722 on the single dose pharmacokinetics (PK) of ethinyl estradiol and levonorgestrel.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Period 1, participants will receive a single dose of ethinyl estradiol and levonorgestrel. In Period 2, participants will receive multiple daily doses of ABBV-722 and a single dose of ethinyl estradiol and levonorgestrel.
Drug: Ethinyl Estradiol + Levonorgestrel · Drug: ABBV-722
Drug pages: Ethinyl Estradiol · Levonorgestrel
Oral
Oral
Maximum Observed Plasma Concentration (Cmax) of Ethinyl Estradiol and Levonorgestrel
Cmax of Ethinyl Estradiol and Levonorgestrel.
Time frame: Up to Day 5 in Period 1 and between Days 14-21 in Period 2
Time to Cmax (Tmax) of Ethinyl Estradiol and Levonorgestrel
Tmax of Ethinyl Estradiol and Levonorgestrel.
Time frame: Up to Day 5 in Period 1 and between Days 14-21 in Period 2
Terminal Phase Elimination Rate Constant (β) of Ethinyl Estradiol and Levonorgestrel
β of Ethinyl Estradiol and Levonorgestrel.
Time frame: Up to Day 5 in Period 1 and between Days 14-21 in Period 2
Terminal Phase Elimination Half-Life (t1/2) of Ethinyl Estradiol and Levonorgestrel
t1/2 of Ethinyl Estradiol and Levonorgestrel.
Time frame: Up to Day 5 in Period 1 and between Days 14-21 in Period 2
Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUCt) of Ethinyl Estradiol and Levonorgestrel
AUCt of Ethinyl Estradiol and Levonorgestrel.
Time frame: Up to Day 5 in Period 1 and between Days 14-21 in Period 2
Area Under the Plasma Concentration-Time Curve From Time 0 to Infinite Time (AUCinf) of Ethinyl Estradiol and Levonorgestrel
AUCinf of Ethinyl Estradiol and Levonorgestrel.
Time frame: Up to Day 5 in Period 1 and between Days 14-21 in Period 2
Number of Participants with Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time frame: Up to Approximately 82 Days
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2026 to primary completion in Jul 2026, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ethinyl Estradiol · Levonorgestrel · ABBV-722